Enovis (NYSE:ENOV) Director Sharon Wienbar Purchases 907 Shares of Company Stock

Key Points

• Enovis Director Sharon Wienbar bought 907 shares at $27.55 each, spending about $24,988 and increasing her stake by 2.16% to 42,853 shares.
• Enovis beat quarterly estimates, reporting EPS of $0.88 versus $0.77 expected and revenue of $558.73 million, up 1.8% year over year.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $38.62; shares traded at $28.25 in the report.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Sharon Wienbar acquired 907 shares of the company's stock in a transaction that occurred on Friday, November 6th. The stock was purchased at an average price of $27.55 per share, for a total transaction of $24,987.85. Following the acquisition, the director directly owned 42,853 shares of the company's stock, valued at $1,180,600.15. The trade was a 2.16% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Enovis Stock Down 1.0%

NYSE ENOV traded down $0.29 during trading on Tuesday, reaching $28.25. The company's stock had a trading volume of 1,596,570 shares, compared to its average volume of 1,879,434. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $1.63 billion, a PE ratio of 8.44 and a beta of 1.31. The business has a 50-day moving average price of $20.05 and a 200-day moving average price of $23.14. Enovis Corporation has a 1-year low of $16.70 and a 1-year high of $32.41.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The company had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same period in the previous year, the firm posted $0.75 earnings per share. The company's revenue for the quarter was up 1.8% compared to the same quarter last year. On average, research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ENOV. Needham & Company LLC upped their price objective on shares of Enovis from $34.00 to $38.00 and gave the stock a "buy" rating in a report on Thursday, November 5th. Citigroup restated a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Wall Street Zen upgraded Enovis from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Citizens Jmp reduced their price target on Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a research report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, November 2nd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.62.

Institutional Trading of Enovis

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE acquired a new position in Enovis in the 2nd quarter valued at $11,502,000. First National Bank of Omaha bought a new position in Enovis in the 2nd quarter worth $1,250,000. Legal & General Group Plc bought a new position in Enovis in the 2nd quarter worth $2,753,000. Man Group plc acquired a new position in Enovis during the 2nd quarter worth $8,711,000. Finally, Jupiter Topco LLC acquired a new position in Enovis during the 2nd quarter worth $2,346,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.